According to Secretary Fortunato Dela Peña of the Department of Science and Technology (DOST), the clinical trials for Lagundi as a supplemental treatment for individuals with COVID-19 will start by August 1, 2020 or earlier if the Food and Drug Administration (FDA) clearance is released.
Here’s the statement of DOST Secretary Dela Peña during the Laging Handa Virtual Briefing today, July 21, 2020.
“Ang aim ng ating study, na sisimulan sa August 1 or earlier kung makakalabas na ‘yong FDA clearance, ay mapakita na ito ay makakabuti para ma-address ‘yong mga symptoms.”
(The aim of our study, which will start by August 1 or earlier if the FDA clearance is released, is to show if it is good to address the symptoms of COVID-19.)
DOST Secretary Dela Peña also added that Tawa-Tawa is approved as a health supplement for dengue while the Lagundi is approved drug for cough and related ailments. Both have the potential to treat COVID-19 because of its anti-viral properties.
Lagundi as Adjuvant Therapy
Secretary Dela Peña said that Lagundi will be given as adjuvant therapy or as a supplement to other medicines the doctors will give to COVID-19 patients.
“Ito ay binibigay na adjuvant therapy or parang supplement doon sa iba pa nilang binibigay na gamot ng kanilang mga doktor,“
COVID-19 Patient Progress Using Lagundi
“‘Yan din ay magsisilbing parang research para makita kung ‘yon bang probability kung magpro-progress ‘yong mga mild to moderate and severe ay mababawasan kung bibigyan ng lagundi. Kasi nga meron na siyang mga napatunayang characteristics or anti-viral properties na puwedeng gamitin sa COVID-19.“